Competing interests
ONCOLOGY
C.N.H. reports funded research from Novartis; speaker fees from Novartis, Janssen, CTI, Celgene, and Medscape; and advisory board membership for Incyte, CTI, Sierra Oncology, Novartis, Celgene, Roche, AOP pharma, Geron, and AstraZeneca. A.J.M. reports funded research from Novartis, Celgene/BMS and consultancy for Abbvie, CTI, and Gilead. S.K. reports funded research and advisory board membership for Novartis. J.E. reports advisory board membership for Novartis, Incyte and Celgene/BMS. M.F.M. reports consultancies for Celgene and BMS; and advisory board membership for Novartis, Jazz, and Abbvie. S.N. reports speaker fees for Takeda, Celgene, Novartis, MSD and Alexion. D.M. reports consultancy for Incyte, Pfizer, Novartis, and Bristol-Myers Squibb. M.W.D. reports funded research from Blueprint Medicine Corporation and advisory board membership for Bristol-Myers Squibb, Novartis, Gilead, Pfizer, Jazz, Takeda, and Astellas. The remaining authors declare no competing financial interests. A.L.G. reports speaker fees from Novartis and advisory board membership AOP pharma and BMS.